Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Denton

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Plos Medicine|October 18, 2017
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trialsSanjay Basu, Jeremy B Sussman, Joseph Rigdon, et al.
Health Care Management Science|October 25, 2022
Monitoring policy in the context of preventive treatment of cardiovascular diseaseDaniel F Otero-Leon, Mariel S Lavieri, Brian T Denton, et al.
Plos Medicine|September 16, 2021
Correction: Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trialsSanjay Basu, Jeremy B Sussman, Joseph Rigdon, et al.
Urology|September 12, 2015
Factors Influencing Selection of Active Surveillance for Localized Prostate CancerJianyu Liu, Paul R Womble, Selin Merdan, et al.
Cancer Medicine|November 7, 2020
Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studiesWeiyu Li, Brian T Denton, Daan Nieboer, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 22, 2013
Estimating the cost of no-shows and evaluating the effects of mitigation strategiesBjorn P Berg, Michael Murr, David Chermak, et al.
Diabetes Care|February 28, 2014
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?Yuanhui Zhang, Rozalina G McCoy, Jennifer E Mason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2019
<sup>18</sup>F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness AnalysisChristine L Barnett, Matthew S Davenport, Jeffrey S Montgomery, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 3, 2011
Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherenceJennifer E Mason, Darin A England, Brian T Denton, et al.
Diabetes Care|August 23, 2014
Response to comments on Zhang et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345Yuanhui Zhang, Rozalina G McCoy, Jennifer E Mason, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Plos Medicine|October 18, 2017
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trialsSanjay Basu, Jeremy B Sussman, Joseph Rigdon, et al.
Health Care Management Science|October 25, 2022
Monitoring policy in the context of preventive treatment of cardiovascular diseaseDaniel F Otero-Leon, Mariel S Lavieri, Brian T Denton, et al.
Plos Medicine|September 16, 2021
Correction: Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trialsSanjay Basu, Jeremy B Sussman, Joseph Rigdon, et al.
Urology|September 12, 2015
Factors Influencing Selection of Active Surveillance for Localized Prostate CancerJianyu Liu, Paul R Womble, Selin Merdan, et al.
Cancer Medicine|November 7, 2020
Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studiesWeiyu Li, Brian T Denton, Daan Nieboer, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 22, 2013
Estimating the cost of no-shows and evaluating the effects of mitigation strategiesBjorn P Berg, Michael Murr, David Chermak, et al.
Diabetes Care|February 28, 2014
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?Yuanhui Zhang, Rozalina G McCoy, Jennifer E Mason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2019
<sup>18</sup>F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness AnalysisChristine L Barnett, Matthew S Davenport, Jeffrey S Montgomery, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 3, 2011
Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherenceJennifer E Mason, Darin A England, Brian T Denton, et al.
Diabetes Care|August 23, 2014
Response to comments on Zhang et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345Yuanhui Zhang, Rozalina G McCoy, Jennifer E Mason, et al.
Pageof 4